Madhu Kumar
Stock Analyst at Goldman Sachs
(2.83)
# 1,498
Out of 5,182 analysts
142
Total ratings
55.1%
Success rate
19.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $196.52 | -5.86% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $7.84 | -23.47% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $7.76 | +119.07% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.41 | +65.98% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $272.52 | -43.12% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $65.32 | -18.86% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $12.53 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $73.91 | -1.23% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $40.94 | +244.41% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $21.39 | +58.95% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $3.44 | +74.42% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $8.59 | +62.98% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $31.58 | -84.17% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.91 | +174.91% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $10.44 | +752.49% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $5.84 | +1,954.79% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.63 | +523.62% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.91 | +897.44% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $18.03 | +216.14% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.20 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.93 | +96,684.60% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $10.37 | +92.86% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,600 → $4,000 | $5.80 | +68,865.52% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $46.48 | -24.70% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.77 | +190.49% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $27.87 | +1,708.40% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $305.54 | -24.72% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $24.82 | +4,432.63% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.48 | +2,602.70% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $36.62 | -41.29% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $48.79 | -51.83% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $196.52
Upside: -5.86%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $7.84
Upside: -23.47%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $7.76
Upside: +119.07%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.41
Upside: +65.98%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $272.52
Upside: -43.12%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $65.32
Upside: -18.86%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $12.53
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $73.91
Upside: -1.23%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $40.94
Upside: +244.41%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $21.39
Upside: +58.95%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $3.44
Upside: +74.42%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $8.59
Upside: +62.98%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $31.58
Upside: -84.17%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.91
Upside: +174.91%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $10.44
Upside: +752.49%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $5.84
Upside: +1,954.79%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.63
Upside: +523.62%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.91
Upside: +897.44%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $18.03
Upside: +216.14%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.20
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.93
Upside: +96,684.60%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $10.37
Upside: +92.86%
Mar 13, 2020
Maintains: Buy
Price Target: $5,600 → $4,000
Current: $5.80
Upside: +68,865.52%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $46.48
Upside: -24.70%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.77
Upside: +190.49%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $27.87
Upside: +1,708.40%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $305.54
Upside: -24.72%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $24.82
Upside: +4,432.63%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.48
Upside: +2,602.70%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $36.62
Upside: -41.29%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $48.79
Upside: -51.83%